Sanofi (SNY -0.91%) reported earnings from the quarter that were below analyst expectations, driven (in part) by a strong euro and currency conversion issues. That said, there were other disappointments as well -- Lantus, Sanofi's flagship insulin product, was up 13.5% in constant currencies to just under 1.5 billion euros, a little lighter than analysts had anticipated.
Nonetheless, Sanofi's management is guiding for 4% to 7% revenue growth (at constant currencies) over the next year, driven by several potential exciting pipeline candidates, including U-300 and alirocumab.
In this segment from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass break down the earnings and what investors should watch for moving forward at Sanofi.
